The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation
Clinical trial NCT05092815 · UNKNOWN
Trial details
- NCT number
- NCT05092815
- Sponsor
- Shanghai Henlius Biotech
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-06
- Primary completion
- 2024-06-30
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.